Business Context and Reporting Period
Company: StemCells, Inc. (Note: Input metadata referenced "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2010
Business Overview: A biopharmaceutical company focused on the research, development, and commercialization of stem cell therapeutics. Key programs include HuCNS-SC cells for neuronal ceroid lipofuscinosis (NCL) and Pelizaeus-Merzbacher disease (PMD), and human liver engrafting cells (hLEC). The company also commercializes cell culture products and technologies acquired from Stem Cell Sciences Plc (SCS) in April 2009.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Total Revenue | $474,404 | $322,053 |
| Gross Profit | $405,780 | $262,528 |
| Net Loss | $(10,734,422) | $(16,647,911) |
| Net Loss Per Share (Basic & Diluted) | $(0.09) | $(0.17) |
| Cash and Cash Equivalents (End of Period) | $30,765,504 | $36,760,470 |
| Total Assets | $42,393,640 | $51,190,324 |
| Total Liabilities | $14,431,497 | $20,695,257 |
| Stockholders' Equity | $27,962,143 | $30,495,067 |
Debt and Liquidity: The company holds approximately $783,000 in outstanding principal on industrial revenue bonds (capital leases) and has significant warrant liabilities valued at $5.72 million. Cash flow from operations was negative $13.75 million for the six-month period, offset by $6.44 million in financing activities, primarily from the sale of common stock.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 47% year-over-year to $474,404, driven by the consolidation of two quarters of revenue from the acquired SCS operations (compared to one quarter in 2009) and a 42% increase in licensing and grant revenue.
- Net Loss Reduction: Net loss decreased by approximately $5.9 million (35%) to $10.7 million. This improvement was significantly aided by a $3.96 million gain from the change in fair value of warrant liabilities, compared to a $2.65 million loss in the prior year.
- Operating Expenses: Total operating expenses increased 3% to $15.06 million. Research and Development (R&D) expenses rose 7% due to the inclusion of the acquired U.K. operations and increased clinical trial costs for the PMD program. Wind-down expenses decreased 47% to $291,168, primarily due to the completion of the Australia site closure.
- Balance Sheet: Total assets decreased by $8.8 million, largely due to a reduction in cash and a decrease in the fair value of warrant liabilities. Total liabilities decreased by $6.26 million, driven by a $3.96 million reduction in the warrant liability and paydowns of accrued wind-down expenses.
Guidance, Outlook, and Risks
- Clinical Progress: The company received FDA authorization in May 2010 to proceed with a second clinical trial for NCL. Enrollment for the Phase I PMD trial began in February 2010, with a goal to complete enrollment by year-end.
- Capital Needs: Management states the company has incurred significant operating losses since inception and expects to incur additional losses in the foreseeable future. It relies on cash reserves, equity/debt offerings, and grants to fund operations. There is no assurance that additional financing will be available on acceptable terms.
- Financing Activity: In June 2010, the company sold 7 million shares to an institutional investor for net proceeds of approximately $5.7 million. An agreement exists for the investor to purchase an additional 5 million shares in approximately 12 weeks.
- Legal Contingencies: Ongoing patent infringement litigation against Neuralstem, Inc. continues. The company has capitalized $750,000 in litigation costs to offset future royalty payments to NeuroSpheres.
- Wind-Down Obligations: The company maintains a reserve of approximately $4.03 million for the wind-down of its former Rhode Island facility, with lease obligations extending to 2013. A smaller reserve of $61,000 remains for the Australia site closure.
Key Facts for Investor Verification
- Liquidity Runway: Verify the sufficiency of the $30.8 million cash balance against the projected burn rate, given the company's reliance on external financing and the uncertainty of future capital markets.
- Warrant Liability Volatility: Note that the reported net loss is significantly impacted by non-cash adjustments to the warrant liability ($3.96 million gain). Investors should assess operating performance excluding this volatile item.
- Rhode Island Lease: Confirm the status of the $4.03 million wind-down reserve and the company's ability to sublease the facility to reduce the net cash outflow of approximately $748,000 projected for the remainder of 2010.
- Clinical Trial Timelines: Monitor the initiation of the second NCL trial and the enrollment progress of the PMD trial, as delays could materially increase R&D costs and delay potential revenue.
- Revenue Sustainability: Assess the sustainability of the 47% revenue increase, which was partially driven by the consolidation of acquired operations and specific grant receipts, rather than organic product sales growth (which declined 40% in Q2).